TY  - JOUR

T1  - Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

JO  - RHEUMATOLOGY

PY  - 2008/10/01

AU  - Wailoo A

AU  - Bansback N

AU  - Chilcott J

ED  - 

DO  - DOI: 10.1093/rheumatology/ken326

VL  - 47

IS  - 10

SP  - 1590

EP  - 1590

Y2  - 2024/12/22

ER  -